Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

Endometriosis Clinical Trial

— ELTA  

Official title:

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03481842
• Other study ID #: C99884.337/18
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: October 10, 2021
• Est. completion date: October 10, 2021

Study information

• Verified date: October 2021
• Source: BioGene Pharmaceutical Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.

Types of endometriosis:

Endometriosis is divided into genital and extragenital. Genital endometriosis is internal and external. When the inner is affected by the uterus, with the external - the ovaries, tubes, vagina and external genital organs are affected. Extragenital endometriosis can affect various organs of the abdominal cavity.

Drug treatment does not show high effectiveness. Surgery / laparoscopic is currently considered the gold standard treatment for this problem, including infertility treatment.

The purpose of our studies is to achieve substantial results with respect to tolerability, safety and clinical efficacy of vaginal suppository ELTA for treatment of the endometriosis.

Methods:

Phase I clinical trial to be conducted at Cancer Center to hold under the aegis UniversitätsSpital Zürich from May 2018 to September 2018.

Ninety-four patients with the form of genital endometriosis will take part in the studies. The study was approved by the Ethics Committee at the Cancer Institute no C99884.01FH339

Description:

The composition of the endometrium includes epithelial cell layers lining the uterine cavity, and deeper stroma, including the secretory glands. Each layer is characterized by the presence of a large number of blood vessels, through which a sufficient amount of blood is delivered. A large number of these vessels and arteries go to the surface layers due to myometrium and form a capillary network in the stroma.

In the vaginal suppositories, the investigators applied minimally therapeutic doses of inhibitors of neoangiogenesis, as well as other components that caused the pathological growth of the endometrium.

Anti-angiogenic therapy - inhibition of proliferative processes in the vascular wall of capillaries and small vessels in the endometrium, is the determining factor of the therapeutic effect of endometriosis when treated with vaginal suppositories.

The composition of the suppository:

• Axitinib, Afatinib, Linifanib (ABT-869) in a minimally sufficient therapeutic doses

• Auxiliary substances that ensure a uniform release of active components from suppositories, taking into account the dependence of this process on the chemical nature of the basis, surfactant, dissolution medium.

(the composition and amount of excipients are maximally optimal for bioavailability of drugs from suppositories, taking into account the pharmacokinetics, pharmacodynamics and synergy of active drugs) This therapy has a slight teratogenic effect, which should be taken into account when planning pregnancy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 10, 2021
• Est. primary completion date: October 10, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years to 60 Years

Eligibility

Inclusion Criteria:

• verification of endometriosis

• signed agreement of informed consent

• agreement with information on the nature, relevance and scope of the investigation, as well as the expected results and undesirable consequences of IMD

Exclusion Criteria:

• use of not permitted contraception or not willing to use contraception

• pregnancy or lactation

• planned pregnancy in the next 36 months with the consent to participate in that clinical trial

• use of any other intravaginal medicinal product or medical device

• known hypersensitivity to one or more of the active and / or inactive ingredients

• acute or chronic renal failure

• acute or chronic heart failure

• the patient's reluctance to follow the trial protocol

• chronic alcoholism

• drug addiction

• use of antidepressants (during participation in trial)

Related Conditions & MeSH terms

• Endometriosis
• Endometriosis Externa
• Endometriosis Ovary
• Endometriosis, Rectum

Intervention

Biological:
• Linifanib
in a minimally sufficient therapeutic dose

Drug:
• BIBW2992
in a minimally sufficient therapeutic dose
• Axitinib
in a minimally sufficient therapeutic dose

Locations

Country	Name	City	State
Switzerland	BioGene Pharmaceutical Ltd.	Basel	?âl?

Sponsors (1)

Lead Sponsor	Collaborator
BioGene Pharmaceutical Ltd.

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Objective findings	Each of the objective symptoms (scored from 0 [none/normal] to 3 [severe]) from the first visit (after the first application).; dryness, itching, hyperemia of the perineum - 1 point,; pain syndrome with itching / dryness or without - 2 points,; bleeding with pain syndrome (or other symptoms / without them - 3 points,; A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)	7 weeks
Other	Global judgement of tolerability	Global judgement of tolerability by investigator and patients. The scores of the Clinical Global Impression (CGI) Scale.	4 weeks
Other	Safety evaluation of therapy	Safety evaluation of therapy. Drugs safety will be evaluated by assessment of adverse events ( ADRs).	15 weeks
Other	Serious Adverse Event.	Occurrence of AE / SAE / ADE / SADE. Characteristics of occured AE / SAE / ADE / SADE	up to 15 weeks
Other	Change in pH-value from vaginal smear	pH-value from vaginal smear at every visit for each patient after the 3rd and 6th week of application of suppositories.	up to 6 weeks
Other	Change in Vaginal flora	Vaginal flora (Lactobacillus spp., Atopobium vaginae and Gardnerella vaginalis) on the first day of intake (before using the first suppository) and on the day of termination of therapy	up to 15 weeks
Other	Other signs of assessing the hip therapy	Mandatory Clinical blood test for each patient after the 3rd and 6th week of application of suppositories.; A control blood test on the first day of the 15th week after the start of the first suppository	up to 15 weeks
Primary	Local tolerability of the vaginal suppository ELTA defined as a cumulative sum of clinical signs for each patient	Local tolerability of the vaginal suppositories ELTA will be defined as a cumulative sum score of the solicited local /vaginal (consisting of subjectively experienced symptoms rated by the patient: burning, itching, bleeding, pain, dryness and objectively documented findings rated by the physician: redness, petechial bleeding, dryness, swelling) for each patient after every weeks of application (scored from 0 [none/normal] to 5 [severe]) Weekly visit of patients every seventh day from the beginning of treatment.; SCALE EVALUATION EVENTS; burning - 2 points,; dryness - 1 point,; painful symptom- 3 points,; itching - 1 point,; bleeding - 5 points,; If there is bleeding or the development of edema - the study for the patient will be stopped.	6 weeks
Secondary	Subjective symptoms (local tolerability)	Each of the subjective symptoms (scored from 0 [none/normal] to 5 [severe]) from the first visit (after the first application)/ A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)	7 weeks